Actinium Pharmaceuticals Inc (ATNM) is a Healthcare · Biotechnology company listed on NYSE MKT. Price $1.20 (+0.84%), Market cap $0.04B, 52-week low–high $0.98 ~ $1.94.
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent
Financial statements, price targets, institutional (13F) holdings and related news for Actinium Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Actinium Pharmaceuticals Inc trades at $1.20 (+0.84%). Real-time quotes and charts are available on BlackAll Trade.
Actinium Pharmaceuticals Inc has a market cap of about $0.04B.
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company